Emerging patent landscape for non-viral vectors used for gene therapy

Nat Biotechnol. 2020 Feb;38(2):151-157. doi: 10.1038/s41587-019-0402-x.

Virginia Picanço-Castro^{1

2}, Cristiano Gonçalves Pereira^{3

4}, Dimas Tadeu Covas^{5

3}, Geciane Silveira Porto^{4

6}, Aglaia Athanassiadou⁷, Marxa Leão Figueiredo^{8

9}

¹ Department of Basic Medical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA. vpicanco@purdue.edu.
² Center for Cell-based Therapy (CTC), Regional Blood Center of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. vpicanco@purdue.edu.
³ Strategic Partnerships and Business Development Office, Instituto Butantan, São Paulo, Brazil.
⁴ School of Economics, Business Administration and Accounting, University of São Paulo, São Paulo, Brazil.
⁵ Center for Cell-based Therapy (CTC), Regional Blood Center of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
⁶ Institute of Advanced Studies of the University of São Paulo, São Paulo, Brazil.
⁷ Department of General Biology, Medical School, University of Patras, Patras, Greece.
⁸ Department of Basic Medical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA. mlfiguei@purdue.edu.
⁹ Purdue Institute for Drug Discovery & Purdue Center for Cancer Research, Purdue University, West Lafayette, IN, USA. mlfiguei@purdue.edu.

Abstract

An analysis of the emerging patent landscape of gene therapies under development, focusing on non-viral vectors.